SCHEMBL29041928

SCHEMBL29041928

O=C(Cc1cc(Br)ccc1Br)Nc1cc(OC(F)(F)F)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WDR5 P61964 1/20 0.42
▸ RIPK1 Q13546 7/20 0.42
▸ RIPK3 Q9Y572 3/20 0.42
▸ ALDH1A1 P00352 3/20 0.41
▸ GAA P10253 2/20 0.41
▸ POLB P06746 2/20 0.41
▸ THRB P10828 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ DDR1 Q08345 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ NLRP3 Q96P20 1/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ KDR P35968 1/20 0.38
▸ GRK2 P25098 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31417741 0.73 EPHX2 (0.47) ALDH1A1GAAPOLBTHRBNPC1
SCHEMBL27352139 0.73 EPHX2 (0.47) ALDH1A1GAAPOLBTHRBNPC1
SCHEMBL16879519 0.73 NPC1 (0.52) RIPK1RIPK3ALDH1A1GAANPC1
SCHEMBL26090529 0.72 KDR (0.43) RIPK1RIPK3ALDH1A1POLBKDR
SCHEMBL27150691 0.71 KMT2A (0.46) ALDH1A1GAAPOLBTHRBNPC1
SCHEMBL31417701 0.71 NPC1 (0.47) ALDH1A1GAAPOLBTHRBNPC1
SCHEMBL16045456 0.70 ALDH1A1 (0.55) ALDH1A1POLBNPC1RAB9AMAPT
SCHEMBL29016621 0.70 NLRP3 (0.53) MAPTCA12CA1CA2CA9
SCHEMBL1984984 0.69 SMN1; SMN2 (0.49) ALDH1A1POLBNPC1RAB9AMAPT
SCHEMBL31417583 0.68 KDR (0.36) WDR5ALDH1A1GAAPOLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12410159-B2 Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors MERCK SHARP & DOHME LLC (US) 2025-09-09 — — US disclosed
EP-4225735-A1 PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2023-08-16 — — EP disclosed
CN-116457346-A Preparation of indolone derivatives as novel diacylglycerol O-acyltransferase 2 inhibitors 默沙东有限责任公司 2023-07-18 — — CN disclosed
WO-2022076496-A1 PREPARATION OF OXINDOLE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12410159-B2 Preparation of oxindole derivatives as novel diacylglyceride O-acyltransferase 2 inhibitors DGAT2, DGAT1, MOGAT2 WDR5 1536/4885RIPK1 2657/4885RIPK3 2636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback